Kyverna Therapeutics, Inc. KYTX Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kyverna Therapeutics, Inc.'s retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kyverna Therapeutics, Inc.'s retained earnings?
- Kyverna Therapeutics, Inc. (KYTX) reported retained earnings of -$464.56M in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s retained earnings changed year-over-year?
- Kyverna Therapeutics, Inc.'s retained earnings decreased by 50.8% year-over-year, from -$308.16M to -$464.56M.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s retained earnings?
- Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s retained earnings has grown at a 76.7% compound annual growth rate (CAGR), from -$136.04M to -$424.83M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.